New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Nuvation Bio Inc. (NUVB) vs Novavax, Inc. (NVAX)

Nuvation Bio Inc. and Novavax, Inc. are both Biotechnology companies. Nuvation Bio Inc. is the larger, with a market value of $1.4B against $1.3B — 1.1× the size. Nuvation Bio Inc. grew revenue faster over the last twelve months: 654.2% against −61.3%. Novavax, Inc. has the higher net margin (−18.6% vs −67.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Novavax, Inc. leads on 10 and Nuvation Bio Inc. on 5.

Valuation

Metric NUVB NVAX Biotechnology median
P/E n/m n/m 8.26
P/S 6.65 3.10 9.20
P/B 5.88 n/m 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m n/m 0.67
EV/Sales 4.77 2.30 9.05
Earnings yield (10.35%) (5.95%) (34.24%)
Free cash flow yield (8.07%) (19.23%) (24.77%)

Profitability

Metric NUVB NVAX Biotechnology median
Gross margin 85.79% 78.01% 70.18%
Operating margin (61.17%) (21.23%) 0.00%
Net margin (67.38%) (18.64%) 0.00%
Free cash flow margin (53.62%) (59.09%) 0.00%
Return on equity (49.09%) 41.08% (51.58%)
Return on assets (19.70%) (7.42%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NUVB NVAX Biotechnology median
Revenue growth (TTM) 654.19% (61.33%) 7.20%
EPS growth (last fiscal year) 71.56% 309.76% 29.04%
Revenue growth, 5-year CAGR — 18.76% 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NUVB NVAX Biotechnology median
Debt to equity 1.25 (1.35) 0.00
Current ratio 7.45 2.15 4.83
Net debt to EBITDA 2.26 (1.04) 1.01

Dividend

Metric NUVB NVAX Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric NUVB NVAX Biotechnology median
Market cap 1.43b 1.27b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack